Using Wegovy Off Label: What UK Patients Should Know

Step 1: understand what Wegovy's licence actually covers

A medicine licence sets out the specific conditions, patient groups and doses that the manufacturer tested and that the regulator (the MHRA) has approved. For Wegovy, that means semaglutide at a maintenance dose of 2.4 mg weekly, for adults with obesity (BMI 30 or above) or overweight (BMI 27–29.9) combined with at least one weight-related condition such as high blood pressure, raised cholesterol or type 2 diabetes. The MHRA's guidance on semaglutide on the NHS medicines pages sets this out clearly.

Wegovy's licensed indications expanded in 2026. In March 2026 NICE recommended it for certain patients within specialist NHS weight management services under NICE technology appraisal TA875. In July 2026 the MHRA granted a conditional approval for Wegovy to treat MASH, a form of fatty liver disease. And in June 2026 the MHRA approved a once-daily oral semaglutide tablet (also branded Wegovy) for weight management. Each of those is a licensed indication. Anything beyond them sits off-label.

It is worth being clear about one thing many people get wrong: Ozempic is not a lower-dose version of Wegovy for weight loss. It is the same molecule at different doses, licensed specifically and only for type 2 diabetes. Prescribing Ozempic for weight management would be off-label use, which is why weight-loss patients should be on Wegovy, not Ozempic.

Step 2: how off-label prescribing works under UK law

Off-label prescribing is entirely legal in the UK. Doctors and independent prescribers do it routinely, particularly when good clinical evidence supports a use that the manufacturer has not yet sought or received a formal licence for. The prescriber takes on extra professional and legal responsibility: they must be satisfied that evidence supports the decision, that the patient gives informed consent knowing the medicine is being used outside its licence, and that the benefit outweighs the risk for that specific individual.

For Wegovy, a prescriber might use it off-label in a number of scenarios: a BMI just below the licensed threshold where clinical need is clear; an adolescent in an exceptional case reviewed by a specialist; or a maintenance dose adjustment not precisely described in the summary of product characteristics. These decisions rest with the prescriber. No online pharmacy or service should be presenting off-label semaglutide as a straightforward product choice, it requires careful, documented clinical reasoning on a case-by-case basis.

If you are exploring how semaglutide works and wondering whether your situation might call for off-label use, the starting point is an honest conversation with a prescriber, not a search for a supplier willing to look the other way. Those are quite different things.

Step 3: the situations where off-label Wegovy comes up most often

In practice, the most common off-label Wegovy scenario that UK patients ask about is a BMI slightly below the licensed threshold, someone at BMI 26 with significant metabolic risk who has read about the medicine and wants access. Prescribers in the UK can exercise clinical judgement here, but responsible practice requires documented evidence that the benefit is clear and the risks understood. Most regulated services, including specialist NHS services, stay within or close to licensed criteria precisely because the evidence base is strongest there.

A second scenario involves the timing of dose changes. The licensed titration schedule moves up roughly every four weeks, but individual patients sometimes plateau or experience persistent side effects, and prescribers may adjust timing accordingly. That is a clinical decision made within a treatment relationship, distinct from a patient self-directing their own dose outside a prescriber's oversight.

The cost of treatment is a genuine factor for many people weighing up their options. For a sense of what private Wegovy treatment typically costs in the UK, our Wegovy price comparison page explains what the market looks like and what a legitimate private prescription usually includes. Understanding cost is reasonable; using cost as a reason to seek out an unlicensed or unregulated supply is not a safe trade-off.

For anyone already on treatment and thinking about breaks or stopping, guidance on coming off Wegovy and a weaning approach are questions to work through with your prescriber rather than manage independently. The same applies to short treatment gaps.

Step 4: what matters before considering any semaglutide treatment

Whether you are looking at licensed use or wondering about a scenario that sits at the edge of the label, a thorough clinical assessment is the non-negotiable starting point. At nume, every consultation is read by a GPhC-registered independent prescriber (a real clinician, not an automated system) and they review each case on its own merits. They check your health history, current medicines, and whether treatment is appropriate before any prescription is issued.

Our Wegovy overview explains the treatment in full, and our clinical team's approach is outlined on our prescribers' page. If you have questions before starting, our FAQs cover the most common ones, or you can get in touch directly. When you are ready, starting a free consultation is the right first step, it costs nothing and gives you an honest clinical answer.